LINK . SPRINGER . COM {}

Detected CMS Systems:

Plone (6 occurrences)

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Link.springer.com Make Money
Keywords
Topics
Questions
Schema
External Links
Analytics And Tracking
Libraries
CDN Services

We are analyzing https://link.springer.com/article/10.1186/s12943-021-01426-3.

Title:
Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine | Molecular Cancer
Description:
With advances in the discovery of the clinical and molecular landscapes of prostate cancer (PCa), implementation of precision medicine-guided therapeutic testing in the clinic has become a priority. Patient derived organoids (PDOs) are three-dimensional (3D) tissue cultures that promise to enable the validation of preclinical drug testing in precision medicine and coclinical trials by modeling PCa for predicting therapeutic responses with a reliable efficacy. We evaluate the advances in 3D culture and PDO use to model clonal heterogeneity and screen for effective targeted therapies, with a focus on the technological advances in generating PDOs. Recent innovations include the utilization of PDOs both in original research and/or correlative studies in clinical trials to examine drug effects within the PCa tumor microenvironment (TME). There has also been a significant improvement with the utilization of various extracellular matrices and single cell assays for the generation and long-term propagation of PDOs. Single cell derived PDOs could faithfully recapitulate the original tumor and reflect the heterogeneity features. While most PDO use for precision medicine understandably involved tissues derived from metastatic patients, we envision that the generation of PDOs from localized PCa along with the incorporation of cells of the TME in tissue models would fulfill the great potential of PDOs in predicting drug clinical benefits. We conclude that single cell derived PDOs reiterate the molecular features of the original tumor and represent a reliable pre-clinical PCa model to understand individual tumors and design tailored targeted therapies.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Link.springer.com operates using PLONE.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

pca, cells, prostate, cancer, pubmed, tumor, pdos, cell, article, organoids, google, scholar, culture, cas, derived, drug, patient, central, models, organoid, precision, cultures, single, therapy, medicine, studies, growth, luminal, molecular, tissue, human, pdo, clinical, model, tme, patients, stem, response, preclinical, metastatic, lines, epithelial, immune, therapeutic, patientderived, targeted, microenvironment, generation, tissues, grown,

Topics {✒️}

low-attachment dishes/multiwell plates article download pdf castration-resistant prostate cancer close patho-physiological relevance patient-derived hydrogel organoids patient-derived cancer organoids myeloid-derived suppressor cells micro-gravity simulated condition patient-derived organoid xenografts detecting tmprss-erg fusion hydrogel-based 3d model precision medicine-based approach personalized medicine approaches luminal stem/progenitor cells high-throughput culture platform pdx-derived organoid model therapeutic decision-making process htert-immortalized primary nonmalignant long-term propagating organoids vivo tumor-stromal interactions robust anti-tumor responses recapitulated inter-patient heterogeneity prostate cancer research rho kinase inhibitor long-term organoid culture enable targeted therapy single cell sequencing mainstay pre-clinical model prostate cancer resulting patient derived explants organoid lines derived privacy choices/manage cookies patient-derived models patient derived organoids single multipotent stem predominantly bone- tropic prostate epithelial cell prostate cancer organoids karthaus wr patient-derived xenografts dna/rna sequencing metastatic prostate cancer single cell assays distinct cell types patient derived tumors prostate cancer specimens single-cell analysis prostate cancer cells stem cell markers prostate cancer growth

Questions {❓}

Tumor-infiltrating mesenchymal stem cells: drivers of the immunosuppressive tumor microenvironment in prostate cancer?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine
         description:With advances in the discovery of the clinical and molecular landscapes of prostate cancer (PCa), implementation of precision medicine-guided therapeutic testing in the clinic has become a priority. Patient derived organoids (PDOs) are three-dimensional (3D) tissue cultures that promise to enable the validation of preclinical drug testing in precision medicine and coclinical trials by modeling PCa for predicting therapeutic responses with a reliable efficacy. We evaluate the advances in 3D culture and PDO use to model clonal heterogeneity and screen for effective targeted therapies, with a focus on the technological advances in generating PDOs. Recent innovations include the utilization of PDOs both in original research and/or correlative studies in clinical trials to examine drug effects within the PCa tumor microenvironment (TME). There has also been a significant improvement with the utilization of various extracellular matrices and single cell assays for the generation and long-term propagation of PDOs. Single cell derived PDOs could faithfully recapitulate the original tumor and reflect the heterogeneity features. While most PDO use for precision medicine understandably involved tissues derived from metastatic patients, we envision that the generation of PDOs from localized PCa along with the incorporation of cells of the TME in tissue models would fulfill the great potential of PDOs in predicting drug clinical benefits. We conclude that single cell derived PDOs reiterate the molecular features of the original tumor and represent a reliable pre-clinical PCa model to understand individual tumors and design tailored targeted therapies.
         datePublished:2021-09-29T00:00:00Z
         dateModified:2021-09-29T00:00:00Z
         pageStart:1
         pageEnd:13
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s12943-021-01426-3
         keywords:
            Prostate cancer
            Patient derived organoids
            Precision medicine
            Targeted therapy
            Cancer Research
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01426-3/MediaObjects/12943_2021_1426_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01426-3/MediaObjects/12943_2021_1426_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01426-3/MediaObjects/12943_2021_1426_Fig3_HTML.png
         isPartOf:
            name:Molecular Cancer
            issn:
               1476-4598
            volumeNumber:20
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Sahithi Pamarthy
               affiliation:
                     name:Rutgers Cancer Institute of New Jersey, Rutgers University
                     address:
                        name:Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hatem E. Sabaawy
               url:http://orcid.org/0000-0002-7976-303X
               affiliation:
                     name:Rutgers Cancer Institute of New Jersey, Rutgers University
                     address:
                        name:Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, USA
                        type:PostalAddress
                     type:Organization
                     name:The State University of New Jersey
                     address:
                        name:Clinical Investigations and Precision Therapeutics Program, Devision of Medical Oncology, Rutgers, The State University of New Jersey, New Brunswick, USA
                        type:PostalAddress
                     type:Organization
                     name:RBHS-Robert Wood Johnson Medical School
                     address:
                        name:Departments of Pathology and Laboratory Medicine, RBHS-Robert Wood Johnson Medical School, New Brunswick, USA
                        type:PostalAddress
                     type:Organization
                     name:The State University of New Jersey
                     address:
                        name:Departments of Medicine, RBHS-Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine
      description:With advances in the discovery of the clinical and molecular landscapes of prostate cancer (PCa), implementation of precision medicine-guided therapeutic testing in the clinic has become a priority. Patient derived organoids (PDOs) are three-dimensional (3D) tissue cultures that promise to enable the validation of preclinical drug testing in precision medicine and coclinical trials by modeling PCa for predicting therapeutic responses with a reliable efficacy. We evaluate the advances in 3D culture and PDO use to model clonal heterogeneity and screen for effective targeted therapies, with a focus on the technological advances in generating PDOs. Recent innovations include the utilization of PDOs both in original research and/or correlative studies in clinical trials to examine drug effects within the PCa tumor microenvironment (TME). There has also been a significant improvement with the utilization of various extracellular matrices and single cell assays for the generation and long-term propagation of PDOs. Single cell derived PDOs could faithfully recapitulate the original tumor and reflect the heterogeneity features. While most PDO use for precision medicine understandably involved tissues derived from metastatic patients, we envision that the generation of PDOs from localized PCa along with the incorporation of cells of the TME in tissue models would fulfill the great potential of PDOs in predicting drug clinical benefits. We conclude that single cell derived PDOs reiterate the molecular features of the original tumor and represent a reliable pre-clinical PCa model to understand individual tumors and design tailored targeted therapies.
      datePublished:2021-09-29T00:00:00Z
      dateModified:2021-09-29T00:00:00Z
      pageStart:1
      pageEnd:13
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s12943-021-01426-3
      keywords:
         Prostate cancer
         Patient derived organoids
         Precision medicine
         Targeted therapy
         Cancer Research
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01426-3/MediaObjects/12943_2021_1426_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01426-3/MediaObjects/12943_2021_1426_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-021-01426-3/MediaObjects/12943_2021_1426_Fig3_HTML.png
      isPartOf:
         name:Molecular Cancer
         issn:
            1476-4598
         volumeNumber:20
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Sahithi Pamarthy
            affiliation:
                  name:Rutgers Cancer Institute of New Jersey, Rutgers University
                  address:
                     name:Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hatem E. Sabaawy
            url:http://orcid.org/0000-0002-7976-303X
            affiliation:
                  name:Rutgers Cancer Institute of New Jersey, Rutgers University
                  address:
                     name:Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, USA
                     type:PostalAddress
                  type:Organization
                  name:The State University of New Jersey
                  address:
                     name:Clinical Investigations and Precision Therapeutics Program, Devision of Medical Oncology, Rutgers, The State University of New Jersey, New Brunswick, USA
                     type:PostalAddress
                  type:Organization
                  name:RBHS-Robert Wood Johnson Medical School
                  address:
                     name:Departments of Pathology and Laboratory Medicine, RBHS-Robert Wood Johnson Medical School, New Brunswick, USA
                     type:PostalAddress
                  type:Organization
                  name:The State University of New Jersey
                  address:
                     name:Departments of Medicine, RBHS-Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Molecular Cancer
      issn:
         1476-4598
      volumeNumber:20
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Rutgers Cancer Institute of New Jersey, Rutgers University
      address:
         name:Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, USA
         type:PostalAddress
      name:Rutgers Cancer Institute of New Jersey, Rutgers University
      address:
         name:Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, USA
         type:PostalAddress
      name:The State University of New Jersey
      address:
         name:Clinical Investigations and Precision Therapeutics Program, Devision of Medical Oncology, Rutgers, The State University of New Jersey, New Brunswick, USA
         type:PostalAddress
      name:RBHS-Robert Wood Johnson Medical School
      address:
         name:Departments of Pathology and Laboratory Medicine, RBHS-Robert Wood Johnson Medical School, New Brunswick, USA
         type:PostalAddress
      name:The State University of New Jersey
      address:
         name:Departments of Medicine, RBHS-Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Sahithi Pamarthy
      affiliation:
            name:Rutgers Cancer Institute of New Jersey, Rutgers University
            address:
               name:Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, USA
               type:PostalAddress
            type:Organization
      name:Hatem E. Sabaawy
      url:http://orcid.org/0000-0002-7976-303X
      affiliation:
            name:Rutgers Cancer Institute of New Jersey, Rutgers University
            address:
               name:Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, USA
               type:PostalAddress
            type:Organization
            name:The State University of New Jersey
            address:
               name:Clinical Investigations and Precision Therapeutics Program, Devision of Medical Oncology, Rutgers, The State University of New Jersey, New Brunswick, USA
               type:PostalAddress
            type:Organization
            name:RBHS-Robert Wood Johnson Medical School
            address:
               name:Departments of Pathology and Laboratory Medicine, RBHS-Robert Wood Johnson Medical School, New Brunswick, USA
               type:PostalAddress
            type:Organization
            name:The State University of New Jersey
            address:
               name:Departments of Medicine, RBHS-Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, USA
      name:Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, USA
      name:Clinical Investigations and Precision Therapeutics Program, Devision of Medical Oncology, Rutgers, The State University of New Jersey, New Brunswick, USA
      name:Departments of Pathology and Laboratory Medicine, RBHS-Robert Wood Johnson Medical School, New Brunswick, USA
      name:Departments of Medicine, RBHS-Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, USA

External Links {🔗}(192)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.35s.